Mifamurtide |
| Katalog-Nr.GC36609 |
Mifamurtid (MTP-PE), ein Analogon des Muramyl-Dipeptids (MDP), ist ein unspezifischer Immunmodulator, der durch Stimulierung der Immunantwort Makrophagen und Monozyten aktiviert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 83461-56-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].
[1]. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53. [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *